駆虫薬の世界市場レポート 2025年

駆虫薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.3％で41億1,000万米ドルに成長します。この予測期間における成長は、世界の寄生虫感染症例の増加、家畜やペットにおける駆虫薬の使用事例の増加、認知度の向上と健康への取り組み、海外旅行の増加などに起因すると考えられます。予測期間における主な動向としては、併用療法に対する需要の高まり、薬剤耐性管理への注目の高まり、個別化医療の採用拡大、治療モニタリングにおける遠隔医療の拡大、新規薬剤標的に関する研究の増加、予防ヘルスケア対策の重視などが挙げられます。

寄生虫感染症の有病率の高さは、今後の駆虫薬市場の成長を牽引すると予想されます。寄生虫感染症は、原虫、ワーム、外部寄生虫など、宿主に寄生するか宿主の内部に生息する生物によって引き起こされる疾患です。これらの感染症は、劣悪な衛生環境、汚染された食物や水、感染した個体や動物との密接な接触、不十分な衛生状態、清潔な資源へのアクセス不足などの要因によって悪化します。駆虫薬は、寄生虫を標的にして宿主の体内から駆除することにより、寄生虫による感染症を治療するために使用されます。これらの薬剤は寄生虫の生理機能を破壊し、寄生虫を排出または死滅させる。例えば、2023年7月、米国を拠点とする国立公衆衛生機関である疾病対策予防センター（CDC）は、フロリダ州におけるシクロスポラ症患者が2021年の254例から2022年には513例へと2倍に増加したと報告しました。このように、寄生虫感染症の高い流行が駆虫薬市場の成長を促進しています。

駆虫薬市場の主要企業は、複数の寄生虫に対する包括的な防御を提供する革新的な併用薬の開発に注力しています。駆虫薬の配合剤とは、2種類以上の駆虫薬をブレンドした製剤で、ヒトと動物の両方の寄生虫感染に対する有効性を高めるものです。これらの薬剤は相乗的に作用し、活性範囲を拡大し、薬剤耐性の発現を遅らせ、寄生虫の既存の耐性に対処します。例えば、2022年1月、米国の動物用医薬品会社であるゾエティス・インク（Zoetis Inc.）は、犬のライム病を引き起こすボレリア・バーグドルフェリ（Borrelia burgdorferi）による感染症を予防することができるシンパリカ・トリオ（Simparica Trio）の効能・効果の承認を米国食品医薬品局（FDA）から取得しました。Simparica Trioは、サロラナー、モキシデクチン、ピランテルという3つの有効成分を配合し、ノミ、マダニ、心虫、回虫、鉤虫を幅広く予防します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界駆虫薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の駆虫薬市場：成長率分析
• 世界の駆虫薬市場の実績：規模と成長, 2019-2024
• 世界の駆虫薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界駆虫薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の駆虫薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベンゾイミダゾール
• 大環状ラクトン
• ピラジノイソキノロン
• テトラヒドロピリミジン
• その他の薬物クラス
• 世界の駆虫薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界の駆虫薬市場感染タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 線虫感染症
• 条虫感染症
• 吸虫感染症
• 混合感染
• 世界の駆虫薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 小売薬局
• オンライン薬局
• 獣医クリニックと用品店
• 世界の駆虫薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 人間用駆虫薬
• 獣医駆虫薬
• 世界の駆虫薬市場ベンゾイミダゾールの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルベンダゾール
• メベンダゾール
• フェンベンダゾール
• オクスフェンダゾール
• チアベンダゾール
• 世界の駆虫薬市場大環状ラクトンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イベルメクチン
• モキシデクチン
• ドラメクチン
• エプリノメクチン
• ミルベマイシンオキシム
• 世界の駆虫薬市場ピラジノイソキノロンのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラジカンテル
• シスチサイド
• 世界の駆虫薬市場テトラヒドロピリミジンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ピランテルパモ酸塩
• 酒石酸ピランテル
• 世界の駆虫薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イミダゾチアゾール
• アミノアセトニトリル誘導体
• スピロインドール
• ヒ素剤

第7章 地域別・国別分析

• 世界の駆虫薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の駆虫薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 駆虫薬市場：競合情勢
• 駆虫薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Novartis AG
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Limited
• Zoetis Inc.
• Hetero Labs Limited
• Sun Pharmaceutical Industries Ltd.
• Galderma S.A.
• Cipla Inc.
• Ferring Pharmaceuticals Inc.
• Amneal Pharmaceuticals, Inc.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Ltd.
• Mankind Pharma Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 駆虫薬市場2029：新たな機会を提供する国
• 駆虫薬市場2029：新たな機会を提供するセグメント
• 駆虫薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anthelmintic drugs are medications designed to treat infections caused by parasitic worms, or helminths. These drugs function by either killing the worms directly or disrupting their reproductive capabilities. They are commonly prescribed for conditions such as roundworm, tapeworm, and hookworm infections.

The primary classes of anthelmintic drugs include benzimidazoles, macrocyclic lactones, pyrazinoisoquinolones, tetrahydropyrimidines, and others. Benzimidazoles are a group of organic compounds featuring a benzene ring fused with an imidazole ring. They are utilized in various applications, including as pharmaceutical agents for treating parasitic infections and as key components in some synthetic materials. These drugs can be administered orally or via injection to treat a range of infections, including nematode, cestode, trematode, and mixed infections. They are distributed through multiple channels, such as hospitals and clinics, retail pharmacies, online pharmacies, and veterinary clinics and supply stores, and are used in both human and veterinary anthelmintics.

The anthelmintic drugs market research report is one of a series of new reports from The Business Research Company that provides anthelmintic drugs market statistics, including the anthelmintic drugs industry's global market size, regional shares, competitors with an anthelmintic drugs market share, detailed anthelmintic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anthelmintic drugs industry. This anthelmintic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anthelmintic drugs market size has grown strongly in recent years. It will grow from $3.16 $ billion in 2024 to $3.34 $ billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the high prevalence of helminth infections, increasing public health initiatives, rise in pharmaceutical research and development, increasing awareness and education, and economic growth.

The anthelmintic drugs market size is expected to see strong growth in the next few years. It will grow to $4.11 $ billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing cases of parasitic infections globally, growing use of anthelmintics in livestock and pets, increasing awareness and health initiatives, and increased international travel. Major trends in the forecast period include rising demand for combination therapies, increasing focus on drug resistance management, growing adoption of personalized medicine, expansion of telemedicine in treatment monitoring, increasing research on novel drug targets, and emphasis on preventive healthcare measures.

The high prevalence of parasitic infections is anticipated to drive the growth of the anthelmintic drugs market in the future. Parasitic infections are diseases caused by organisms that live on or inside a host, such as protozoa, worms, or ectoparasites. These infections are exacerbated by factors such as poor sanitation, contaminated food or water, close contact with infected individuals or animals, inadequate hygiene, and lack of access to clean resources. Anthelmintic drugs are used to treat infections caused by parasitic worms by targeting and eliminating these parasites from the host's body. These medications disrupt the physiological functions of the parasites, leading to their expulsion or death. For example, in July 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported a twofold increase in cyclosporiasis cases in Florida, from 254 cases in 2021 to 513 cases in 2022. Thus, the high prevalence of parasitic infections is fueling the growth of the anthelmintic drugs market.

Leading companies in the anthelmintic drugs market are focusing on developing innovative combination drugs to offer comprehensive protection against multiple parasites. Combination anthelmintic drugs are formulations that blend two or more anthelmintic agents to enhance efficacy against parasitic infections in both humans and animals. These drugs work synergistically to expand the range of activity, delay the onset of drug resistance, and address existing resistance in parasites. For instance, in January 2022, Zoetis Inc., a US-based animal health company, received approval from the U.S. Food and Drug Administration for Simparica Trio, a new label indication that allows it to prevent infections caused by Borrelia burgdorferi, which causes Lyme disease in dogs. Simparica Trio combines three active ingredients-sarolaner, moxidectin, and pyrantel-to provide broad protection against fleas, ticks, heartworms, roundworms, and hookworms.

In July 2023, Bayer AG, a Germany-based pharmaceutical and biotechnology company, partnered with the Swiss Tropical and Public Health Institute (Swiss TPH) to develop anthelmintic drug compounds for treating parasitic infections. This collaboration aims to assess the safety and efficacy of emodepside, a compound originally developed for veterinary use, for treating soil-transmitted helminths in humans. The goal is to provide a new treatment option and advance global health efforts by addressing a major public health challenge in developing regions. The Swiss Tropical and Public Health Institute (Swiss TPH) is a Switzerland-based research institute focused on global health and tropical diseases.

Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company

North America was the largest region in the anthelmintic drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthelmintic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anthelmintic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anthelmintic drugs market consists of sales of albendazole, mebendazole, praziquantel, levamisole, piperazine, and ivermectin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anthelmintic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anthelmintic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anthelmintic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anthelmintic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Benzimidazoles; Macrocyclic lactones; Pyrazinoisoquinolones; Tetrahydropyrimidines; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable
• 3) By Infection Type: Nematode Infections; Cestode Infections; Trematode Infections; Mixed Infections
• 4) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Online Pharmacies; Veterinary Clinics And Supply Stores
• 5) By Application: Human Anthelmintics; Veterinary Anthelmintics
• Subsegments:
• 1) By Benzimidazoles: Albendazole; Mebendazole; Fenbendazole; Oxfendazole; Thiabendazole
• 2) By Macrocyclic Lactones: Ivermectin; Moxidectin; Doramectin; Eprinomectin; Milbemycin Oxime
• 3) By Pyrazinoisoquinolones: Praziquantel; Cysticide
• 4) By Tetrahydropyrimidines: Pyrantel Pamoate; Pyrantel Tartrate
• 5) By Other Drug Classes: Imidazothiazoles; Aminoacetonitrile Derivatives; Spiroindoles; Arsenicals
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anthelmintic Drugs Market Characteristics

3. Anthelmintic Drugs Market Trends And Strategies

4. Anthelmintic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Anthelmintic Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anthelmintic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anthelmintic Drugs Market Growth Rate Analysis
• 5.4. Global Anthelmintic Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anthelmintic Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anthelmintic Drugs Total Addressable Market (TAM)

6. Anthelmintic Drugs Market Segmentation

• 6.1. Global Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benzimidazoles
• Macrocyclic lactones
• Pyrazinoisoquinolones
• Tetrahydropyrimidines
• Other Drug Classes
• 6.2. Global Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nematode Infections
• Cestode Infections
• Trematode Infections
• Mixed Infections
• 6.4. Global Anthelmintic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Retail Pharmacies
• Online Pharmacies
• Veterinary Clinics And Supply Stores
• 6.5. Global Anthelmintic Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Anthelmintics
• Veterinary Anthelmintics
• 6.6. Global Anthelmintic Drugs Market, Sub-Segmentation Of Benzimidazoles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Albendazole
• Mebendazole
• Fenbendazole
• Oxfendazole
• Thiabendazole
• 6.7. Global Anthelmintic Drugs Market, Sub-Segmentation Of Macrocyclic Lactones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ivermectin
• Moxidectin
• Doramectin
• Eprinomectin
• Milbemycin Oxime
• 6.8. Global Anthelmintic Drugs Market, Sub-Segmentation Of Pyrazinoisoquinolones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Praziquantel
• Cysticide
• 6.9. Global Anthelmintic Drugs Market, Sub-Segmentation Of Tetrahydropyrimidines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pyrantel Pamoate
• Pyrantel Tartrate
• 6.10. Global Anthelmintic Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imidazothiazoles
• Aminoacetonitrile Derivatives
• Spiroindoles
• Arsenicals

7. Anthelmintic Drugs Market Regional And Country Analysis

• 7.1. Global Anthelmintic Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anthelmintic Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anthelmintic Drugs Market

• 8.1. Asia-Pacific Anthelmintic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anthelmintic Drugs Market

• 9.1. China Anthelmintic Drugs Market Overview
• 9.2. China Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anthelmintic Drugs Market

• 10.1. India Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anthelmintic Drugs Market

• 11.1. Japan Anthelmintic Drugs Market Overview
• 11.2. Japan Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anthelmintic Drugs Market

• 12.1. Australia Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anthelmintic Drugs Market

• 13.1. Indonesia Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anthelmintic Drugs Market

• 14.1. South Korea Anthelmintic Drugs Market Overview
• 14.2. South Korea Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anthelmintic Drugs Market

• 15.1. Western Europe Anthelmintic Drugs Market Overview
• 15.2. Western Europe Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anthelmintic Drugs Market

• 16.1. UK Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anthelmintic Drugs Market

• 17.1. Germany Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anthelmintic Drugs Market

• 18.1. France Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anthelmintic Drugs Market

• 19.1. Italy Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anthelmintic Drugs Market

• 20.1. Spain Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anthelmintic Drugs Market

• 21.1. Eastern Europe Anthelmintic Drugs Market Overview
• 21.2. Eastern Europe Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anthelmintic Drugs Market

• 22.1. Russia Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anthelmintic Drugs Market

• 23.1. North America Anthelmintic Drugs Market Overview
• 23.2. North America Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anthelmintic Drugs Market

• 24.1. USA Anthelmintic Drugs Market Overview
• 24.2. USA Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anthelmintic Drugs Market

• 25.1. Canada Anthelmintic Drugs Market Overview
• 25.2. Canada Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anthelmintic Drugs Market

• 26.1. South America Anthelmintic Drugs Market Overview
• 26.2. South America Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anthelmintic Drugs Market

• 27.1. Brazil Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anthelmintic Drugs Market

• 28.1. Middle East Anthelmintic Drugs Market Overview
• 28.2. Middle East Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anthelmintic Drugs Market

• 29.1. Africa Anthelmintic Drugs Market Overview
• 29.2. Africa Anthelmintic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anthelmintic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anthelmintic Drugs Market, Segmentation By Infection Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anthelmintic Drugs Market Competitive Landscape And Company Profiles

• 30.1. Anthelmintic Drugs Market Competitive Landscape
• 30.2. Anthelmintic Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Anthelmintic Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Teva Pharmaceutical Industries Limited
• 31.6. Zoetis Inc.
• 31.7. Hetero Labs Limited
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Galderma S.A.
• 31.10. Cipla Inc.
• 31.11. Ferring Pharmaceuticals Inc.
• 31.12. Amneal Pharmaceuticals, Inc.
• 31.13. Zydus Lifesciences Limited
• 31.14. Glenmark Pharmaceuticals Ltd.
• 31.15. Mankind Pharma Ltd.

32. Global Anthelmintic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anthelmintic Drugs Market

34. Recent Developments In The Anthelmintic Drugs Market

35. Anthelmintic Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Anthelmintic Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anthelmintic Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anthelmintic Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer